The FDA has issued final guidance which provides the agency’s current thinking on steps to broaden eligibility criteria in clinical trials through inclusive trial practices. The guidance provides recommendations for how to increase enrollment of underrepresented populations in clinical trials.
Read more: FDA Offers Guidance to Enhance Diversity in Clinical Trials, Encourage Inclusivity in Medical Product Development